Please assess the completion status of the following clinical trial:

Trial Title: Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have been treated with diet and exercise and a stable, maximally tolerated dose of immediate-release or extended-release metformin, or the combination of metformin (any dosage) with sulfonylurea/meglitinides for at least 3 months prior to study start~* Have not received thiazolidinediones, or alpha-glucosidase inhibitors for longer than 2 weeks within 3 months prior to study start, and have not received any insulin formulation for more than 14 days (other than in emergency situations) and within 14 days prior to study start~* Have an HbA1c between 6.5% and 10.0%, inclusive~* Have a body mass index (BMI) between 25 kg/m\^2 and 40 kg/m\^2, inclusive~Exclusion Criteria:~* Have type 1 diabetes or known latent autoimmune diabetes in adults~* Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks prior to study start~* Are receiving treatment for gastrointestinal disease with a drug directly affecting gastrointestinal motility (e.g., metoclopramide, cisapride, and chronic macrolide antibiotics)~* Have used any prescription drug to promote weight loss within 3 months prior to study start~* Have received treatment within 30 days prior to study start with a drug that has not received regulatory approval for any indication at the time of study entry~* Have previously completed or withdrawn from this study or any other study investigating exenatide or GLP-1 analogs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide Twice Daily (BID) (Type: EXPERIMENTAL): None
- Premixed Insulin Aspart Twice Daily (BID) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).